Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 5Gynecologic 4Thoracic 3Gastrointestinal 3Dermatologic 3Breast 3Sarcoma 2Plasma cell 1Head & Neck 1CNS 1

Conditions

Pancreatic Neoplasms 22Stomach Neoplasms 19Ovarian Neoplasms 18Colorectal Neoplasms 18Melanoma 15Carcinoma, Hepatocellular 15Carcinoma, Non-Small-Cell Lung 12Breast Neoplasms 11Neoplasm Metastasis 10Uterine Cervical Neoplasms 9Esophageal Neoplasms 9Liver Neoplasms 7Head and Neck Neoplasms 7Anus Neoplasms 7Colonic Neoplasms 6Carcinoma, Renal Cell 6Vaginal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Penile Neoplasms 5Neoplasms 5Mesothelioma 5Lung Neoplasms 5Cholangiocarcinoma 5Triple Negative Breast Neoplasms 4Oropharyngeal Neoplasms 4Neuroblastoma 4Gastrointestinal Neoplasms 4Carcinoma, Merkel Cell 4Vulvar Neoplasms 3Urinary Bladder Neoplasms 3

Interventions

pembrolizumab 23Gemcitabine 9Nivolumab 7Carboplatin 7Trastuzumab 6Early Intervention, Educational 6avelumab 5atezolizumab 5Docetaxel 5Cisplatin 5cemiplimab 4Standard of Care 4Psychiatric Rehabilitation 4Paclitaxel 4Methods 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Fluorouracil 4Fluorodeoxyglucose F18 4Cyclophosphamide 4Counseling 4Albumin-Bound Paclitaxel 4tisotumab vedotin 3pertuzumab 3fludarabine 3Taxes 3Radiotherapy 3Polymerase Chain Reaction 3Gene Expression Profiling 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × fludarabine × Gastrointestinal × Clear all
NCT02869217 2025-12-03

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

University Health Network, Toronto

Phase 1 Active not recruiting
22 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Urinary Bladder Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

NCT04319757 2024-12-05

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

Acepodia Biotech, Inc.

Phase 1 Completed
12 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT02457650 2016-08-03

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Shenzhen Second People's Hospital

Phase 1 Unknown
36 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Melanoma, Multiple Myeloma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡